CRISPR Therapeutics vs Immitra Bio
CRISPR Therapeutics vs Immitra Bio, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CRISPR Therapeutics is on 64/100 and Immitra Bio on 48/100.
Where each one leads
CRISPR Therapeutics
- our overall score: 64/100 against 48/100
- agent readiness: 44/100 against 29/100
- domain rating: 67/100 against 8/100
- funding raised: $547M against $2.6M
Immitra Bio
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CRISPR Therapeutics | Immitra Bio |
|---|---|---|
| What it is | Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology. | Scalable, one-time curative in-vivo gene editing therapies. |
| Category | Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals | Biotechnology, Gene Therapy, Genetics, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2013 | 2024 |
| Headquarters | Zug, Switzerland | Zürich, Switzerland |
| Status | Active | Active |
Size, funding and growth
| Measure | CRISPR Therapeutics | Immitra Bio |
|---|---|---|
| Total funding | $547M | $2.6M |
| Latest round | Series B | Pre-Seed |
| LinkedIn followers | Not published | 2,336 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CRISPR Therapeutics | Immitra Bio |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 48/100 |
| Traction | 40/100 | 32/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 13/100 | 33/100 |
| Quality | 88/100 | 52/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | F (29/100) |
| Domain ratingLink authority, 0-100 | 67/100 | 8/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CRISPR Therapeutics | Immitra Bio |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Fastly |
| Frameworks | Jquery | Bootstrap |
| Analytics | Google Analytics 4 | Not detected |
CRISPR Therapeutics vs Immitra Bio: common questions
Which is better, CRISPR Therapeutics or Immitra Bio?
On our 0-100 score CRISPR Therapeutics rates higher (64/100 against 48/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do CRISPR Therapeutics and Immitra Bio compare on the numbers?
CRISPR Therapeutics leads on our overall score (64/100 against 48/100), agent readiness (44/100 against 29/100), domain rating (67/100 against 8/100), funding raised ($547M against $2.6M).
Read the full CRISPR Therapeutics review and pricing or the Immitra Bio review and pricing. You can also browse other CRISPR Therapeutics alternatives we track.